Copy to clipboard 
DePuy Synthes reported 1Q19 orthopaedic revenue of USD $2,203MM, -2.1% vs. 1Q18.
- Knee sales were impacted by competitive pressure in the U.S. coupled with declines in EMEA, which were partially offset by increasing uptake of ATTUNE Revision
- Hip sales were supported by strong market demand for the ACTIS stem
- Spine regressed on base business declines
- In trauma, new products like Femoral Recon Nails gained traction supported by a growing market
- Sports Medicine saw double-digit growth in Asia Pacific
- Completed acquisition of Auris Health to enhance digital surgery capabilities, expects the addition to complement Orthotaxy
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
| 1Q19 | 1Q18 | $ Chg | % Chg | |
| Joint Replacement | $846.3 | $867.9 | -$21.6 | -2.5% |
| Knees | $374.4 | $393.2 | -$18.8 | -4.8% |
| Hips | $370.5 | $369.2 | $1.3 | 0.3% |
| Extremities | $101.5 | $105.5 | -$4.0 | -3.8% |
| Spine | $354.4 | $360.5 | -$6.1 | -1.7% |
| Trauma | $654.3 | $663.9 | -$9.6 | -1.4% |
| Sports Medicine | $169.5 | $167.6 | $1.9 | 1.1% |
| Orthobiologics | $94.7 | $101.3 | -$6.6 | -6.5% |
| Other (CMF) | $83.6 | $88.9 | -$5.3 | -5.9% |
| Total | $2,203.0 | $2,250.1 | -$47.1 | -2.1% |
ORTHOWORLD estimates orthopaedic sales by geographic region as follows ($MM).
| Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
| US | $1,317.97 | $1,307.06 | $10.9 | 0.8% |
| Ex-US | $884.98 | $943.04 | -$58.1 | -6.2% |
| EMEA | $398.24 | $424.37 | -$26.1 | -6.2% |
| Asia Pacific | $314.17 | $330.06 | -$15.9 | -4.8% |
| Rest of World | $172.57 | $188.61 | -$16.0 | -8.5% |
| Total | $2,203.0 | $2,250.1 | -$47.1 | -2.1% |
Net earnings for all Johnson & Johnson revenue are as follows.
| 1Q19 | Amount ($MM) | % of Sales |
| Sales | $20,021.0 | |
| Cost of Sales | -$6,615.0 | 33.0% |
| Selling and Admin | -$5,219.0 | 26.1% |
| R & D | -$3,748.0 | 18.7% |
| Other | -$690.0 | 3.4% |
| Net Earnings | $3,749.0 | 18.7% |
Sources: DePuy Synthes Companies of Johnson & Johnson; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
DePuy Synthes reported 1Q19 orthopaedic revenue of USD $2,203MM, -2.1% vs. 1Q18.
Knee sales were impacted by competitive pressure in the U.S. coupled with declines in EMEA, which were partially offset by increasing uptake of ATTUNE Revision
Hip sales were supported by strong market demand for the ACTIS stem
Spine...
DePuy Synthes reported 1Q19 orthopaedic revenue of USD $2,203MM, -2.1% vs. 1Q18.
- Knee sales were impacted by competitive pressure in the U.S. coupled with declines in EMEA, which were partially offset by increasing uptake of ATTUNE Revision
- Hip sales were supported by strong market demand for the ACTIS stem
- Spine regressed on base business declines
- In trauma, new products like Femoral Recon Nails gained traction supported by a growing market
- Sports Medicine saw double-digit growth in Asia Pacific
- Completed acquisition of Auris Health to enhance digital surgery capabilities, expects the addition to complement Orthotaxy
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
| 1Q19 | 1Q18 | $ Chg | % Chg | |
| Joint Replacement | $846.3 | $867.9 | -$21.6 | -2.5% |
| Knees | $374.4 | $393.2 | -$18.8 | -4.8% |
| Hips | $370.5 | $369.2 | $1.3 | 0.3% |
| Extremities | $101.5 | $105.5 | -$4.0 | -3.8% |
| Spine | $354.4 | $360.5 | -$6.1 | -1.7% |
| Trauma | $654.3 | $663.9 | -$9.6 | -1.4% |
| Sports Medicine | $169.5 | $167.6 | $1.9 | 1.1% |
| Orthobiologics | $94.7 | $101.3 | -$6.6 | -6.5% |
| Other (CMF) | $83.6 | $88.9 | -$5.3 | -5.9% |
| Total | $2,203.0 | $2,250.1 | -$47.1 | -2.1% |
ORTHOWORLD estimates orthopaedic sales by geographic region as follows ($MM).
| Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
| US | $1,317.97 | $1,307.06 | $10.9 | 0.8% |
| Ex-US | $884.98 | $943.04 | -$58.1 | -6.2% |
| EMEA | $398.24 | $424.37 | -$26.1 | -6.2% |
| Asia Pacific | $314.17 | $330.06 | -$15.9 | -4.8% |
| Rest of World | $172.57 | $188.61 | -$16.0 | -8.5% |
| Total | $2,203.0 | $2,250.1 | -$47.1 | -2.1% |
Net earnings for all Johnson & Johnson revenue are as follows.
| 1Q19 | Amount ($MM) | % of Sales |
| Sales | $20,021.0 | |
| Cost of Sales | -$6,615.0 | 33.0% |
| Selling and Admin | -$5,219.0 | 26.1% |
| R & D | -$3,748.0 | 18.7% |
| Other | -$690.0 | 3.4% |
| Net Earnings | $3,749.0 | 18.7% |
Sources: DePuy Synthes Companies of Johnson & Johnson; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
